达罗他胺联合ADT和多西他赛治疗欧洲mHSPC患者的疗效与安全性:ARASENS III期试验亚组分析
ARASENS试验中,达罗他胺联合雄激素剥夺治疗(ADT)和多西他赛显著降低转移性激素敏感性前列腺癌(mHSPC)患者32.5%的死亡风险(HR 0.68)。本分析评估欧洲患者亚组(472例,占36%)的疗效与安全性。结果显示,达罗他胺组降低37%死亡风险(HR 0.63),并延迟至mCRPC、疼痛进展、首次症状性骨骼事件及后续系统抗肿瘤治疗的时间,安全性与总体人群一致。
要点
- 欧洲mHSPC患者中,达罗他胺联合ADT和多西他赛降低37%死亡风险(HR 0.63)。
- 达罗他胺延迟至mCRPC、疼痛进展、首次SSE及后续治疗的时间。
- 严重TEAE发生率达罗他胺组37.9% vs 安慰剂组43.1%,安全性与总体人群一致。
核心结论
- 在欧洲mHSPC患者中,达罗他胺联合ADT和多西他赛改善总生存并延迟至mCRPC和疼痛进展时间。
- 达罗他胺耐受性良好,两组TEAE发生率相似,疗效与安全性与总体ARASENS人群一致。
研究设计与样本
- ARASENS为III期随机对照试验,患者1:1随机接受达罗他胺600 mg或安慰剂每日两次,联合ADT和多西他赛。
- 本分析纳入ARASENS中472例(36%)欧洲患者,达罗他胺组240例,安慰剂组232例。
- 主要终点为总生存,次要终点包括至mCRPC时间、至疼痛进展时间、至首次SSE时间、至后续系统抗肿瘤治疗时间及安全性。
主要发现
- 欧洲患者中,达罗他胺降低37%死亡风险(HR 0.63;95% CI 0.48-0.83)。
- 达罗他胺延迟至mCRPC、至疼痛进展、至首次SSE及至后续系统抗肿瘤治疗的时间。
- 严重TEAE发生率达罗他胺组37.9% vs 安慰剂组43.1%,总体人群为44.8% vs 42.3%。
临床怎么用
- 对于欧洲mHSPC患者,达罗他胺联合ADT和多西他赛可作为有效且耐受性良好的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In ARASENS, risk of death was significantly reduced by 32.5% with darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.57-0.80; p < 0.001) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We assessed efficacy and safety of darolutamide in European patients from ARASENS. METHODS: Patients were randomized 1:1 to darolutamide 600 mg or placebo twice daily in combination with ADT and docetaxel. Primary endpoint was overall survival. Secondary endpoints included time to metastatic castration-resistant prostate cancer (mCRPC), time to pain progression, time to first symptomatic skeletal event (SSE), time to initiation of subsequent systemic antineoplastic therapy, and safety. RESULTS: In ARASENS, 472 (36%) patients were from Europe; 240 received darolutamide and 232 received placebo. Patient baseline characteristics were similar to those of the overall population. Darolutamide reduced the risk of death by 37% (HR, 0.63; 95% CI, 0.48-0.83), and delayed time to mCRPC, time to pain progression, time to first SSE, and time to initiation of subsequent systemic antineoplastic therapy compared with placebo. Incidences of serious treatment-emergent adverse events (TEAEs) were lower with darolutamide versus placebo (37.9% vs. 43.1%) compared with the overall population (44.8% vs. 42.3%). CONCLUSION: In European patients with mHSPC, darolutamide improved overall survival and secondary endpoints including time to mCRPC and time to pain progression. Darolutamide was well tolerated with similar incidence of TEAEs between treatment groups. Efficacy and safety findings in European patients were consistent with the overall ARASENS population.
引用
- Tombal B, Hussain M, Saad F, et al. Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial. Eur J Cancer. 2026. PMID: 41967349. doi:10.1016/j.ejca.2026.116730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。